Acorda Therapeutics Inc - ACOR STOCK NEWS

Acorda Therapeutics, Inc. (ACOR) faces delisting from Nasdaq following Chapter 11 proceedings and asset acquisition agreement with Merz Therapeutics. The company's common stock will be suspended from trading on April 12, 2024, with a shift to the Pink Open Market expected. Delisting stems from noncompliance with Nasdaq Listing Rules due to the Chapter 11 filing and insufficient stockholders' equity.

Acorda Therapeutics, Inc. files for voluntary Chapter 11 protection to facilitate the sale of its assets to Merz Therapeutics for $185 million. The company aims to ensure uninterrupted patient access to INBRIJA and AMPYRA. The sale process is expected to conclude in June 2024.

Acorda Therapeutics, Inc. (ACOR) cancels Q4 and year-end 2023 earnings call but plans to file Form 10-K on time.

Acorda Therapeutics, Inc. (ACOR) will host a webcast/conference call for its Q4 and year-end 2023 update and financial results on April 1, 2024. Participants can register for the webcast to submit questions for the Q&A session. The presentation will be accessible on the company's website, with a replay available until May 1, 2024.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) has announced that it will regain global commercialization rights to FAMPYRA® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement between the companies, effective January 1, 2025. FAMPYRA is indicated in the European Union and other territories throughout the world for the improvement of walking in adults with multiple sclerosis (MS) with walking disability. Acorda markets the medication as AMPYRA® (dalfampridine) in the United States. Acorda and Biogen are working together toward a transition for Acorda to commercialize and supply FAMPYRA for the great majority of people with MS outside the United States currently being served. Acorda plans to assume commercialization responsibilities as soon as possible during 2024 as marketing authorization transfers and distribution arrangements are finalized for each territory. The company's President and CEO, Ron Cohen, M.D., expressed excitement about bringing FAMPYRA in-house, adding significant value to Acorda and enabling continued access to this important medication for people with MS around the world.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) reported a 32% increase in new INBRIJA prescription requests in Q3 2023 over Q3 2022, with a 38% increase in the first three quarters of 2023 versus the same period in 2022. INBRIJA Q3 2023 U.S. net revenue was $8.1 million, a 4% increase over Q3 2022, while AMPYRA Q3 2023 net revenue was $15.7 million, a 26% decrease over Q3 2022. Biopas Laboratories filed for approval of INBRIJA in six Latin American countries, with expectations of up to five approvals in 2024. The company also expects to file in Chile by the end of 2023 and in Brazil and Mexico in 2024.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call for its third quarter 2023 update and financial results on November 13 at 4:30 p.m. ET. Participants can register for the webcast and submit written questions. The presentation will be available on the company's website. A replay of the call will be accessible until December 12.

Acorda Therapeutics, Inc. announces the submission of new regulatory filings for the approval of INBRIJA® in six Latin American countries. Biopas Laboratories has submitted for marketing approval in Argentina, Colombia, Costa Rica, Ecuador, Panama, and Peru. Additional filings are expected in Chile in late 2023 and in Mexico and Brazil in 2024. Up to five approvals are expected in 2024.

Acorda Therapeutics, Inc. (ACOR) reported Q2 2023 U.S. net revenue of $8.3 million for INBRIJA, a 12% increase from Q2 2022. However, the company revised its 2023 INBRIJA U.S. net revenue guidance to $34-$38 million and does not expect to be cash flow neutral this year. AMPYRA Q2 2023 net revenue was $16.9 million, a 7% decrease from Q2 2022. The company does not expect AMPYRA revenue to continue at the same rate due to generic competition. The company regained Nasdaq compliance after a 1-for-20 reverse split.